Back
liqesr | 56897

Liquid Biopsy breast carcinoma

Keywords:
AKT1
ESR1
Elacestrant
Liquid Biopsy
Next Generation Sequencing
PIK3CA
SERD
breast
breast carcinoma
cellfree DNA
cfDNA
treatment resistance

Status

Material
BCT blood Cell-Free DNA BCT-Tube
Hint
Detection of therapy-relevant variants of the genes ESR1, PIK3CA and AKT1. This analysis may result in excess information. This will be communicated, unless it is noted otherwise when placing the order. As there may also be indications of hereditary changes, the GUMG shall ensure the patient is informed accordingly (see www.viollier.ch/en/SGMG_consent). Tarification: according to Tarmed.
Min. volume 8 mL
Stability
Stability
5 days / 18-25°C; 5 days / 2-8°C
Duration 3 - 5 days
Frequency 2 x per week
Method Next Generation Sequencing

Price/Rate

Price
Price
CHF 2’624.40
Rate
Rate
2'624.40 TP